Real-world characteristics and outcome of patients treated with single-agent ibrutinib for chronic lymphocytic leukemia in Spain (IBRORS-LLC Study)

Ibrutinib demonstrated remarkable efficacy and favorable tolerability in patients with untreated or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), including those with high-risk genetic alterations. The IBRORS-CLL study assessed the characteristics, clinical management and outcome of CLL patients receiving ibrutinib in routine clinical practice in Spain.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 3, 2021 Category: Hematology Authors: Pau Abrisqueta, Javier Loscertales, Maria Jos é Terol, Ángel Ramírez Payer, Macarena Ortiz, Inmaculada Pérez, Carolina Cuellar-García, Margarita Fernández de la Mata, Alicia Rodríguez, Ana Lario, Julio Delgado, Ana Godoy, José Mª Arguiñano Pére Tags: Original Article Source Type: research